Unveiling a New Test for a Deadly Kidney Disease Complication
Scientists from The University of Manchester and Northern Care Alliance NHS Foundation Trust have made a groundbreaking discovery that could revolutionize the way we detect and manage sarcopenia, a serious muscle condition linked to higher mortality in chronic kidney disease (CKD).
The research team has developed a simple yet powerful test called creatinine muscle index (CMI), which combines two routine blood tests, creatinine and cystatin C. This innovative approach allows for the early identification of individuals at risk of sarcopenia, a condition characterized by muscle mass and strength loss, leading to a reduced quality of life.
The study, published in the journal PLOS Medicine, is the first large-scale investigation to demonstrate the effectiveness of CMI in CKD patients. It involved 2,930 adults with non-dialysis CKD from 16 kidney centers across the UK, who were followed for a median of 50 months.
The findings revealed that lower CMI, indicating reduced muscle mass, was strongly associated with weaker hand grip strength, slower walking speed, and a higher risk of sarcopenia. Conversely, higher CMI was linked to a lower risk of death. The average CMI levels in men and women were 864 mg/day and 704 mg/day, respectively.
For every 100 mg/day per 1.73 m² increase in CMI, the risk of death decreased by 15% in men and 23% in women. Moreover, CMI outperformed other cystatin C-creatinine-based measures in predicting mortality and sarcopenia, making it a superior biomarker.
Dr. Thomas McDonnell, the lead author and a researcher at The University of Manchester and a kidney doctor at Salford Royal Hospital, emphasized the significance of this discovery. He stated, 'Sarcopenia in CKD patients is associated with increased mortality, poorer self-reported health-related quality of life, and reduced functional status.'
Dr. McDonnell further highlighted the importance of routine sarcopenia identification in CKD patients, as it opens doors to interventions that can improve their wellbeing. He added, 'Our findings also highlight CMI's superiority over alternative tests, providing exciting evidence for its potential as a blood-based biomarker of sarcopenia and mortality risk.'
This research, funded by Kidney Research UK and the Donal O'Donoghue Renal Research Centre, has the potential to transform patient care by enabling earlier detection and intervention, ultimately reducing the risk of death associated with sarcopenia in CKD patients.
